Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected.
Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year.
Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – $4.8 billion billion.
Adjusted EPS guidance for FY19 raised to a new range of $10.25 – $10.40, vs. earlier guidance of $9.65 – $9.85.
ALXN shares rose 1.7% immediately following the announcement.
On the heels of lawmakers moving closer to passing the stimulus bill, inflations concerns gripped the market after Federal Reserve chief Jerome Powell at a meeting said the reopening would
Though the retail boom triggered by the pandemic was estimated to be short-lived initially, the shopping spree continued as customers stocked up on essential items, concerned about the persistent market
Shares of Gap Inc. (NYSE: GPS) were up 5.8% in afternoon hours on Friday. The stock has gained 103% over the past 12 months. Gap reported mixed results for the